Why your R&D expense line is hiding the real cost of each program

A biotech CFO we work with walked into a quarterly board meeting with a clean set of financials. Total R&D spend was $2.1 million for the quarter. The Profit and Loss report (P&L) showed $2.1 million in R&D expense. Cash flow balanced.

Halfway through the meeting, a board member asked how much had been spent specifically on the Phase II program that quarter.

She could not answer. Not because the spending was not tracked, but because the books had no way to separate Phase II costs from Phase I costs. Every contract research organization (CRO) invoice, every scientific payroll run, every lab supply purchase had gone into the same R&D expense account. The answer to “what did Program B cost?” did not exist in the books.

What clinical stage cost tracking means

Most early-stage biotechs run more than one program at once. They may have a lead candidate in Phase I, a second asset in preclinical development, and platform technology that serves both. Investors, board members, and prospective partners want to know what each program is costing.

Standard accounting software creates a single R&D expense category. Without additional configuration, every research cost goes there. The P&L tells you what you spent on R&D in total. It tells you nothing about what you spent on any individual program.

Clinical stage cost tracking means assigning every cost to the specific program it belongs to. The tool that makes this work inside QuickBooks Online is Classes: a tagging layer that lets you slice any report by program without changing your chart of accounts.

What gets lost without per-program allocation

Several cost categories cause problems when they are not tracked at the program level.

CRO invoices that cover multiple programs. A contract research organization often runs work for two programs under one master service agreement. The invoice arrives as a single amount. Without a split, the entire amount goes into R&D expense and neither program is accountable for its share.

Personnel costs across multiple programs. A scientist who spends 70 percent of her time on the Phase II program and 30 percent on Phase I is a real allocation decision. If her salary is not split by that ratio each month, Phase II cost is understated and Phase I cost is understated in the opposite direction.

Consumables and reagents. Lab supplies are typically purchased in bulk and used across projects. Without a charge-out or allocation system, they sit in one line. A reagent plate used for Phase I work and a plate used for Phase II look identical in the books.

Platform technology and licensing fees. A license paid for a delivery technology that enables both programs is a shared cost. If it goes into one R&D bucket with no attribution, no program ever carries its portion of that cost.

What the quarter actually looked like

When we rebuilt the CFO’s quarter using QuickBooks Classes, here is what the $2.1 million in R&D expense contained.

The board member’s question had an answer: Program B cost $640,000 in the quarter. The approved budget for Program B had been $600,000. The $40,000 overrun came from one additional CRO run that was approved informally and never reconciled against the program budget.

That is a manageable finding. Without program-level tracking, it would have stayed invisible until year-end, when the total R&D line came in over budget and no one could explain where.

Why this matters

Three situations make the absence of per-program tracking a significant problem.

Board and investor reporting. Sophisticated investors expect program-level spend, not a single R&D line. Budget vs. actual by program is a standard request at Series B and beyond. If the books cannot produce it, the finance team produces it manually in a spreadsheet that may or may not reconcile back to the P&L. Either the numbers differ and the board gets conflicting data, or someone spends hours making them match every quarter.

Partnering and licensing discussions. A large pharmaceutical company evaluating an in-licensing deal will ask for a detailed cost history for the program it is considering. It wants to see spend by category, by CRO, by trial phase. A single R&D line provides none of that, and assembling it after the fact from invoices and payroll records is a significant delay in a deal process.

Runway and budget management. When programs share one expense bucket, neither is accountable to its own budget. An overrun in one program is invisible until the total R&D line goes over. Runway calculations built on one R&D number can be materially wrong if one program is consuming well above plan.

What per-program tracking looks like in practice

For biotech clients, we configure QuickBooks Classes to match the company’s active program structure. Each clinical program gets its own class. Shared platform and infrastructure costs get a separate class, typically labeled by function.

Every transaction is tagged at the line level. A CRO invoice that covers both programs is entered as two lines, one per class, using the split agreed to in the work order. Personnel costs are allocated monthly using time percentages reviewed and approved by the CMO or COO. Lab consumables above a minimum dollar threshold are tagged at the point of purchase.

Monthly, each program generates its own P&L by class. Budget vs. actual is visible for every program at once, with no manual spreadsheet layer between the books and the board deck.

Best practices for early-stage biotechs

Four practices that keep program-level cost tracking accurate over time:

• Configure QuickBooks Classes before the next funding round or grant cycle, not after. Retroactive allocation requires estimation and introduces error that is difficult to audit.
• Document the allocation methodology for each cost type in writing. If CRO fees are split 67/33 between Program A and Program B, that percentage should be in the master service agreement or in a written policy, not in someone’s memory.
• Review personnel time allocations monthly, not annually. A scientist’s time split can shift substantially over the course of a trial. Annual allocations produce inaccurate quarterly costs.
• Treat shared platform costs as a distinct class rather than overhead to ignore. The cost of enabling technology is real program cost, and an accurate historical record matters when that platform is licensed, divested, or used to support a future regulatory filing.

Three questions worth asking

If you are not sure how your R&D costs are tracked today, three questions to put to whoever manages the books:

1. What did we spend on each active clinical program last quarter, and was that number pulled directly from the books or assembled from a separate spreadsheet?
2. When a CRO invoice covers more than one program, how is the split determined and who approves it before the invoice is recorded?
3. Does the program-level spend in the board presentation reconcile to the P&L, and if not, what explains the difference?

If those answers are uncertain, the books are not tracking at the program level. The fix is a configuration change, a written allocation policy, and a monthly review process. None of that requires switching accounting software, and all of it can be in place before the next board meeting.

If you want to see where your program reporting stands today, send us a recent quarter of CRO invoices and your current chart of accounts. We will show you what per-program cost tracking would look like in your books and where the gaps are.